α7 Nicotinic Receptor Agonists as Cognitive Treatments: Is Less (or Less Often) More?
Authors:
- Robert W. BuchananRBRobert W. Buchanan
- Robert SchwarczRSRobert Schwarcz
- 1 January 2011
- journal article
- editorial
- Published by Elsevier in Biological Psychiatry
- Vol. 69 (1) , 5-6
Abstract
No abstract availableFunding Information
- Janssen Pharmaceutica
This publication has 9 references indexed in Scilit:
- Immediate and Sustained Improvements in Working Memory After Selective Stimulation of α7 Nicotinic Acetylcholine ReceptorsBiological Psychiatry, 2011
- Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in SchizophreniaBiological Psychiatry, 2010
- Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processesBiochemical Pharmacology, 2009
- Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory studySchizophrenia Research, 2008
- Initial Phase 2 Trial of a Nicotinic Agonist in SchizophreniaAmerican Journal of Psychiatry, 2008
- Aberrant “Default Mode” Functional Connectivity in SchizophreniaAmerican Journal of Psychiatry, 2007
- Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptorsBiochemical Pharmacology, 2007
- Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic–pharmacodynamic discordanceTrends in Pharmacological Sciences, 2005
- Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D1 Receptor StimulationScience, 2000